Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy
Teva's ordinary shares began trading directly on the NYSE today, completing the planned transition away from its American Depositary Shares program, with the ticker unchanged at TEVA on both the NYSE and the Tel Aviv Stock Exchange. CEO Richard Francis called the direct listing another meaningful milestone in Teva's transformation, and CFO Eli Kalif said it strengthens the company's position in U.S. capital markets alongside its recent return to investment-grade credit ratings from all three major agencies.
Key figures
- Credit ratings
- investment-grade at all three major ratings agencies
- Flagship brands yoy growth ytd
- more than 40%
- Pipeline peak revenue potential
- more than $10 billion
- Flagship brands expected 2026 revenue
- $3.7 billion
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.